Your browser is no longer supported. Please, upgrade your browser.
Settings
ADIL Adial Pharmaceuticals, Inc. daily Stock Chart
ADIL [NASD]
Adial Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.89 Insider Own3.40% Shs Outstand11.14M Perf Week-7.42%
Market Cap23.62M Forward P/E- EPS next Y- Insider Trans-28.37% Shs Float7.13M Perf Month-1.85%
Income-7.80M PEG- EPS next Q- Inst Own15.20% Short Float1.22% Perf Quarter32.50%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.03 Perf Half Y8.16%
Book/sh0.85 P/B2.49 EPS next Y- ROA-84.50% Target Price5.00 Perf Year-70.14%
Cash/sh0.76 P/C2.78 EPS next 5Y- ROE-89.30% 52W Range1.34 - 8.00 Perf YTD-12.03%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-73.50% Beta-
Dividend %- Quick Ratio12.20 Sales past 5Y- Gross Margin- 52W Low58.21% ATR0.26
Employees3 Current Ratio12.20 Sales Q/Q- Oper. Margin- RSI (14)46.31 Volatility12.31% 10.04%
OptionableNo Debt/Eq0.00 EPS Q/Q88.70% Profit Margin- Rel Volume0.71 Prev Close2.17
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume84.26K Price2.12
Recom2.00 SMA20-10.67% SMA5010.75% SMA2009.62% Volume59,889 Change-2.30%
Oct-30-18Initiated Maxim Group Buy $5
Oct-11-18Initiated Dawson James Buy
Jan-09-20 09:15AM  Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland ACCESSWIRE
Dec-30-19 05:36AM  Need To Know: Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Insiders Have Been Buying Shares Simply Wall St. +7.75%
Dec-19-19 09:30AM  Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries ACCESSWIRE +6.55%
Dec-16-19 09:00AM  Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker ACCESSWIRE +15.00%
Dec-13-19 09:30AM  Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial ACCESSWIRE +30.95%
Oct-29-19 08:30AM  Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites ACCESSWIRE -5.20%
Oct-17-19 10:30AM  Adial Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Patent for the Treatment of Alcohol Use Disorder in Patients Identified Using a Molecular Genetic Biomarker ACCESSWIRE
Oct-07-19 09:26AM  Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder ACCESSWIRE
Oct-01-19 08:30AM  Adial Files Clinical Trial Application to Commence Phase 3 Trial ACCESSWIRE
Sep-27-19 11:52AM  We Think Adial Pharmaceuticals (NASDAQ:ADIL) Needs To Drive Business Growth Carefully Simply Wall St.
Sep-25-19 09:50AM  Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019 ACCESSWIRE
Sep-11-19 09:15AM  Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial ACCESSWIRE +5.73%
Sep-07-19 09:30AM  Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder ACCESSWIRE
Aug-06-19 04:30PM  Adial Pharmaceuticals' Chief Executive Officer to be Featured Live on Cheddar's ''Closing Bell'' ACCESSWIRE
Jul-29-19 03:01PM  Do Directors Own Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares? Simply Wall St.
Jun-19-19 09:00AM  Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare ACCESSWIRE -5.56%
Jun-13-19 09:35AM  Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder ACCESSWIRE +7.29%
Jun-06-19 09:00AM  Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization ACCESSWIRE +6.77%
May-07-19 09:00AM  Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder ACCESSWIRE
Apr-30-19 09:00AM  Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City ACCESSWIRE
Apr-29-19 11:56AM  Have Insiders Been Buying Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares This Year? Simply Wall St.
Apr-22-19 09:00AM  Adial Pharmaceutical's Chief Medical Officer Dr. Bankole Johnson Featured on NBC West Palm Beach, Florida Affiliate ACCESSWIRE
Apr-11-19 09:00AM  Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy ACCESSWIRE
Apr-04-19 09:00AM  Bankole A. Johnson, M.D., Chief Medical Officer of Adial Pharmaceuticals Delivers Keynote Lecture; Receives Prestigious American Society of Addiction Medicine Award ACCESSWIRE
Apr-03-19 09:00AM  Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D. ACCESSWIRE
Mar-26-19 09:00AM  Adial Pharmaceuticals Announces Appointment of Bankole Johnson, M.D., as Chief Medical Officer ACCESSWIRE
Mar-25-19 08:00AM  Adial Pharmaceuticals Announces Filing to Update the Prior Registration Statement Registering the Shares Underlying the ADILW Warrants ACCESSWIRE
Feb-28-19 03:02PM  Adial CEO: A Medical Solution For Alcoholism Could Be Just Around The Corner Benzinga
09:15AM  Adial Pharmaceuticals Featured on CBS in San Francisco GlobeNewswire
Feb-26-19 08:00AM  Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters Over-Allotment Option GlobeNewswire -7.05%
Feb-21-19 01:35PM  Four Biotech Stocks Setting The Standard On Thursday (2/21/19) ACCESSWIRE +17.80%
08:45AM  Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering GlobeNewswire
Feb-20-19 09:00AM  Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adials AD04 for its Phase 3 Trial GlobeNewswire -6.13%
Feb-15-19 08:30AM  Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse GlobeNewswire
Feb-12-19 09:33AM  Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder GlobeNewswire -9.71%
Feb-07-19 09:15AM  Dr. Bankole A. Johnson, Chairman of Adial Pharmaceuticals, Receives Prestigious American Society of Addiction Medicine Award GlobeNewswire
Feb-01-19 09:20AM  Adial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder GlobeNewswire +25.78%
Jan-24-19 08:30AM  Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants GlobeNewswire +10.19%
Jan-23-19 01:57PM  What Kind Of Investor Owns Most Of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)? Simply Wall St. -6.90%
Jan-17-19 09:00AM  Adial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder GlobeNewswire -6.58%
Jan-15-19 09:05AM  Bankole Johnson, MD and Chairman of the Board of Adial Pharmaceuticals Featured in Second Installment of The Doctors Channel Video Series GlobeNewswire +14.58%
Jan-10-19 08:00AM  Adial Pharmaceuticals to Present at The 2019 Wall Street Conference GlobeNewswire +12.07%
Dec-27-18 10:25AM  These 4 Healthcare Stocks Are Gaining Speed ACCESSWIRE -8.40%
Dec-26-18 04:18PM  Why Adial Pharmaceuticals (ADIL) Stock Is Soaring Today InvestorPlace +27.47%
11:57AM  4 Healthcare Stocks Getting A Boost On Wednesday, Dec. 26, 2018 ACCESSWIRE
07:30AM  Biotech News Driving These Companies ACCESSWIRE
Dec-24-18 08:00AM  Adial Pharmaceuticals Retires All Outstanding Debt GlobeNewswire +15.12%
07:30AM  Biotech Breakout Candidates ACCESSWIRE
Dec-20-18 06:50AM  Today's Research Reports on Trending Tickers: Aduro BioTech and Adial Pharmaceuticals ACCESSWIRE -15.66%
Dec-19-18 09:00AM  Adial Pharmaceuticals Announces Amendment to License Agreement with the University of Virginia Licensing & Ventures Group GlobeNewswire +23.39%
Dec-14-18 06:55AM  Today's Research Reports on Trending Tickers: Adial Pharmaceuticals and Cancer Genetics ACCESSWIRE -8.65%
Dec-13-18 12:49PM  Adial Pharmaceuticals News: ADIL Stock Is Skyrocketing Today InvestorPlace +104.93%
08:00AM  Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl GlobeNewswire
Dec-10-18 08:00AM  Adial Pharmaceuticals Announces Professor Hannu Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki, Finland as Coordinating Principal Investigator for Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder GlobeNewswire -10.50%
Dec-04-18 06:45AM  Adial Pharmaceuticals, Analysts Coverage, Review and Target ACCESSWIRE
Nov-29-18 10:10AM  Healthcare Stocks Following New Market Trends: Premier Health Group (PHGRF) (PHGI), Alliqua BioMedical, Tonix Pharma, & Adial Pharma ACCESSWIRE +112.12%
09:10AM  Adial Pharmaceuticals Establishes Scientific Advisory Board and Appoints Global Thought Leader in the Field of Alcohol Use Disorder GlobeNewswire
Nov-21-18 08:00AM  Adial Pharmaceuticals Chairman Featured in Doctors Channel Video Discussing Alcohol Use Disorder GlobeNewswire +12.59%
07:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Nov-19-18 08:00AM  Adial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder GlobeNewswire
Nov-14-18 08:00AM  Adial Pharmaceuticals Provides Business Update for the Third Quarter of 2018 GlobeNewswire
Nov-08-18 09:20AM  Addiction Drug Developer Adial Pharmaceuticals Receives Notice of Allowance of Canadian Patent for AD04 in Alcohol Use Disorder GlobeNewswire
Oct-23-18 08:00AM  Adial Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference GlobeNewswire +7.88%
Sep-26-18 02:15PM  Adial Pharmaceuticals to Present at The MicroCap Conference on October 1st in New York City ACCESSWIRE
Sep-18-18 07:30AM  Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports No Challenges to European Patent GlobeNewswire +9.59%
Sep-12-18 09:00AM  Alcohol Use Disorder Drug Candidate from Adial Pharmaceuticals Shows Positive Stability Results GlobeNewswire
Sep-04-18 08:00AM  Adial Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell this Morning at 9:30 AM Eastern GlobeNewswire
Aug-27-18 09:00AM  Leading Addiction Focused Company Adial Pharmaceuticals Comments on Lancet Article Reporting Alcohol is the Number One Cause of Death Globally Among Ages 15 to 49 GlobeNewswire -7.08%
Aug-15-18 08:00AM  Adial Pharmaceuticals Announces Appointment of Monika Rogozinska as Senior Vice President of Drug and Business Development GlobeNewswire
Aug-02-18 05:31PM  Dawson James Securities Announces the Closing of Initial Public Offering of Adial Pharmaceuticals, Inc. GlobeNewswire -5.96%
Jul-31-18 04:05PM  Adial Pharmaceuticals Announces Closing of Initial Public Offering GlobeNewswire
Jul-27-18 07:00AM  Adial Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Johnson Bankole A.Chief Medical OfficerDec 12Sale1.00150,000150,000698,336Dec 13 09:00 PM